Measurable Residual Disease Testing in the Community Oncology Setting

In the game of chess, anticipating the correct response to each of your opponent’s moves on the board can ...

FEBRUARY 7, 2024

Columvi Granted Accelerated Approval For Selected Relapsed or Refractory Large B-cell Lymphomas

The FDA granted accelerated approval for glofitamab-gxbm (Columvi, Genentech) for the treatment of adult patients ...

JUNE 18, 2023

Epkinly Approved for Relapsed/Refractory Diffuse Large B-cell Lymphoma and High-Grade B-Cell Lymphoma

The FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab) for relapsed/refractory diffuse large ...

MAY 22, 2023

Polivy Approved for Previously Untreated DLBCL, Not Otherwise Specified, or High-Grade B-Cell Lymphoma

The FDA approved polatuzumab vedotin-piiq (Polivy, Genentech) with R-CHP (rituximab, cyclophosphamide, doxorubicin, ...

APRIL 21, 2023

Novel Agents Expand Rx for Refractory Lymphoma

Treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma have increased dramatically, ...

MAY 29, 2022

R-CHOP14 and 21 Equally Safe and Effective for DLBCL

Fourteen- and 21-day cycles of R-CHOP are similarly safe and effective in the treatment DLBCL, according data ...

NOVEMBER 15, 2018

Rituxan Hycela Approved for FL, DLBCL, CLL

Rituximab and hyaluronidase human (Rituxan Hycela,  Genentech) was approved for subcutaneous injection for the ...

JUNE 23, 2017

Obinutuzumab + CHOP Fails To Beat R-CHOP for DLBCL

Obinutuzumab failed to produce a PFS advantage over rituximab when both drugs were combined with the standard CHOP ...

FEBRUARY 15, 2017